Back to Screener

Jyong Biotech Ltd. Ordinary Shares (MENS)

Price$2.02
Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-100.50%
Price vs S&P 500 (4W)-1.45%
VGM Score33.34
Market Capitalization$153.58M

All Metrics

Indicated Dividend (Annual)$0.00
Price vs S&P 500 (YTD)-57.02%
EPS (TTM)$-0.08
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-0.08
EPS (Annual)$-0.06
Cash / Share (Quarterly)$0.02
ROA (Last FY)-22.48%
EBITD / Share (TTM)$-0.05
Cash Flow / Share (Annual)$-0.04
Net Income / Employee (Annual)$-161,100
Net Interest Coverage (TTM)-1.42x
ROA (TTM)-20.27%
EPS Incl Extra (Annual)$-0.06
Current Ratio (Annual)0.45x
Quick Ratio (Quarterly)0.42x
3-Month Avg Trading Volume0.20M
Revenue / Employee (TTM)$0
52-Week High$67.00
EPS Excl Extra (Annual)$-0.06
26-Week Price Return-92.57%
Quick Ratio (Annual)0.42x
13-Week Price Return-8.18%
Current Ratio (Quarterly)0.45x
Enterprise Value$170.84M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.02
3-Month Return Std Dev83.57%
Net Income / Employee (TTM)$-204,200
Net Interest Coverage (Annual)-1.55x
EPS Basic Excl Extra (Annual)$-0.06
EPS Incl Extra (TTM)$-0.08
Revenue / Share (Annual)$0.00
Year-to-Date Return-48.86%
5-Day Price Return-1.94%
EPS Normalized (Annual)$-0.06
Month-to-Date Return-8.18%
EBITD / Share (Annual)$-0.03
EPS Basic Excl Extra (TTM)$-0.08
Price vs S&P 500 (13W)-16.44%
Beta3.08x
Revenue / Share (TTM)$0.00
52-Week Low$1.43
mGradeD
vgmGradeD
Show chart for

Industry Peers — Pharmaceuticals(550)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
MENSJyong Biotech Ltd. Ordinary Shares
D$2.02
LLYEli Lilly & Co.DBB$1131.42
JNJJohnson & JohnsonDCB$232.77
ABBVABBVIE INC.DCC$227.23
MRKMerck & Co., Inc.CCB$120.79
NVSNovartis AGCCC$149.16
AZNAstraZeneca PLCDBC$185.95
NVONovo-Nordisk A/SBBB$42.96
ABTAbbott LaboratoriesCCD$91.07
PFEPfizer Inc.BCC$26.04
BMYBristol-Myers Squibb Co.BCB$57.27

About

Jyong Biotech is a Taiwan-based biotechnology company focused on developing plant-derived therapeutics for urinary system diseases. Its pipeline includes a lead candidate in NDA submission, a clinical-stage program, and preclinical assets, targeting the U.S., European, and Asian markets.